Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: growthvalue who wrote (26011)	10/6/1998 11:12:00 AM
From: bob zagorin	Respond to of 32384

note last paragraph. Ligand/Panaretin-2: Was Accepted In Canadian Priority Review Dow Jones Newswires SAN DIEGO -- Ligand Pharmaceuticals Inc. (LGND) filed a New Drug Submission with the Health Protection Branch of Canada for Panretin gel 0.1% for the treatment of cutaneous lesions of patients with AIDS-related Kaposi's sarcoma. In a press release Monday, Ligand said the NDS for Panretin gel has been accepted for priority review in Canada. If approved, Panretin gel will be the first topical therapy in Canada for Kaposi's sarcoma, a cancer common in people who have AIDS. The NDS filing is based on Canadian, U.S., European and Australian safety and efficacy data that was also included in the New Drug Application filed with the Food and Drug Administration for Panretin gel in May 1998. Panretin gel was accepted for priority review by the FDA, and has also received orphan drug designation in the U.S. A Marketing Authorization Application filing for Europe, where Ligand intends to be the primary marketer for Panretin gel, is currently under preparation for submission late this year or early next.